Reference
- Paepe D P, Wolf-Peeters D C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007; 21: 37–43
- Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 2002; 7: 239–252
- Lossos I S, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007
- Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–348
- Dai W, Wang Q, Traganos F. Polo-like kinases and centrosome regulation. Oncogene 2002; 21: 6195–6200
- McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, et al. Inhibitors of polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006; 2: 608–617
- van de Weerdt B C, van Vugt M A, Lindon C, Kauw J J, Rozendaal M J, Klompmaker R, et al. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol 2005; 25: 2031–2044
- Zhou T, Aumais J P, Liu X, Yu-Lee L Y, Erikson R L. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003; 5: 127–138
- Shin S, Sung B J, Cho Y S, Kim H J, Ha N C, Hwang J I, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40: 1117–1123
- Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24: 267–276
- Duffy M J, O'Donovan N, Brennan D J, Gallagher W M, Ryan B M. Survivin: a promising tumor biomarker. Cancer Lett 2007
- Sah N K, Khan Z, Khan G J, Bisen P S. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164–171
- Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 815–821
- Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 2006; 106: 247–257
- Lowery D M, Lim D, Yaffe M B. Structure and function of polo-like kinases. Oncogene 2005; 24: 248–259
- Smith M R, Wilson M L, Hamanaka R, Chase D, Kung H, Longo D L, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397–405
- Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte H J, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 543–549
- Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 2794–2797
- Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15: 687–692
- Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70: 126–133
- Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001; 164: 41–49
- Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001; 169: 41–49
- Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148–152
- Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte H J, et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196: 753–759
- Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29: 354–358
- Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60: 240–245
- Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90: 414–418
- Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89: 535–536
- Wheatley S P, McNeish I A. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005; 247: 35–88
- Altieri D C. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5: 447–452
- Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921–1925
- Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005; 46: 225–231